Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i> - and Non– <i>BRCA1/2</i> -Mutant Cancers

Timothy A. Yap, Johann S. de Bono, Mona Parmar et al.|Cancer Discovery|2020

Cited by 134